Response to Letter to the Editor: "Menopausal Hormone Therapy Is Associated With Reduced and Total Visceral Adiposity: The OsteoLaus Cohort"

Georgios E. Papadakis[1] and Olivier Lamy[2,3]

[1]Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, CH-1011 Lausanne, Switzerland; [2]Center of Bone Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, CH-1011 Lausanne, Switzerland; and [3]Service of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, CH-1011 Lausanne, Switzerland

ORCiD numbers: 0000-0002-0099-6755 (G. E. Papadakis).

We thank Dr. Turner and Professor Kerber for their interest in our article on the association between menopausal hormone therapy (MHT) and reduced android and visceral adiposity (1). Their letter brings additional insight to the results of our study, providing important data from animal studies that corroborate our findings and suggest underlying pathophysiological mechanisms.

In our article, we considered the benefits of MHT to derive from the direct effect of estrogen on adipose tissue, given the absence of significant differences between groups regarding potential intermediary factors such as caloric intake and physical activity. Nevertheless, as acknowledged in the article's Discussion, the assessment of confounding factors was only partial, thus preventing us from drawing definitive conclusions. In their letter, Turner *et al.* highlight an elegant study in ovariectomized rodents that revealed that 17β-estradiol supplementation restored normal lipolytic function, in contrast to physical exercise alone (2). These data imply that MHT in our study may have reduced android fat and visceral adipose tissue via alteration of basic lipolytic rate.

The authors attribute the absence of residual effect in past users to the eventual downregulation of estrogen receptor and subsequent loss of function of important estrogen-associated metabolic pathways. Although this speculation remains plausible, we would like to stress that the response of the target organs after MHT withdrawal seems to be tissue-specific, given our previous findings of a less pronounced rebound effect on bone density and microarchitecture (3).

Based on several animal studies, Turner *et al.* (4) support the theory of "eu-estrogenemia," arguing in favor of the critical window hypothesis to explain that the estrogen receptor has distinct responses according to the timing of estrogen administration. Extrapolating these data to humans, we would expect that early MHT use would have more favorable outcomes, as suggested by subgroup analysis of the Women's Health Initiative (5). More recently, the most convincing clinical data in favor of this hypothesis come from the ELITE randomized clinical trial, which showed reduced carotid artery intima-media thickness after 6 months of MHT selectively in early (<6 years) compared with late (>10 years) postmenopausal women (6). In OsteoLaus, however, we were able to detect a benefit for body mass index, android fat, and visceral adipose tissue despite a broader age of the studied population (50 to 80 years). A possible explanation is that MHT duration was long (12.2 $\pm$ 8.8 years), for a mean age of 62.6 $\pm$ 6.7 years in current users. It is likely that MHT was started early after menopause in the majority of the participants, who thus fulfilled the criteria of eu-estrogenemia.

In the light of the aforementioned evidence, we agree with Turner *et al.* that the findings of our observational study should encourage further research to explore the optimal use of MHT.

Acknowledgments

Financial Support: The detailed sources of funding of the OsteoLaus study are listed in the article "Menopausal Hormone

Abbreviation: MHT, menopausal hormone therapy.

ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA

Received 6 August 2018. Accepted 15 August 2018.
First Published Online 20 August 2018

Therapy Is Associated With Reduced and Total Visceral Adiposity: The OsteoLaus Cohort" (1).

Correspondence and Reprint Requests: Georgios E. Papadakis, MD, Service of Endocrinology, Diabetes and Metabolism, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, Avenue de la Sallaz 8-10, CH-1011 Lausanne, Switzerland. E-mail: georgios.papadakis@chuv.ch.

Disclosure Summary: The authors have nothing to disclose.

References

1. Papadakis GE, Hans D, Rodriguez EG, Vollenweider P, Waeber G, Marques-Vidal P, Lamy O. Menopausal hormone therapy is associated with reduced total and visceral adiposity: the OsteoLaus cohort. *J Clin Endocrinol Metab*. 2018;**103**(5):1948–1957.
2. Spangenburg EE, Wohlers LM, Valencia AP. Metabolic dysfunction under reduced estrogen levels: looking to exercise for prevention. *Exerc Sport Sci Rev*. 2012;**40**(4):195–203.
3. Papadakis G, Hans D, Gonzalez-Rodriguez E, Vollenweider P, Waeber G, Marques-Vidal PM, Lamy O. The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal. *J Clin Endocrinol Metab*. 2016;**101**(12):5004–5011.
4. Turner RJ, Kerber IJ. A theory of eu-estrogenemia: a unifying concept. *Menopause*. 2017;**24**(9):1086–1097.
5. Roehm E. A reappraisal of Women's Health Initiative Estrogen-Alone Trial: long-term outcomes in women 50–59 years of age. *Obstet Gynecol Int*. 2015;**2015**:713295.
6. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. *N Engl J Med*. 2016;**374**(13):1221–1231.